

# Nanomedicine: Precision drug delivery and bioavailability.

Emily L. Hayes\*

Department of Medicinal Chemistry, University of Oxford, United Kingdom

## Introduction

Nanocarriers significantly improve the oral bioavailability of various drugs by overcoming barriers like poor solubility, enzymatic degradation, and first-pass metabolism [1].

This crucial advancement means that medications previously limited by how well the body could absorb them can now be delivered more effectively, making treatments more potent and potentially reducing required dosages. The ability to bypass systemic degradation ensures that more of the active compound reaches its intended target. This area of research thoroughly explores various design considerations for these tiny carriers and the underlying mechanisms that facilitate better drug uptake. Nanomaterials are transforming cancer therapy by enabling targeted drug delivery, minimizing systemic toxicity, and enhancing therapeutic efficacy [2].

Precision medicine in oncology heavily relies on these innovations. By directing therapeutic agents specifically to cancerous cells or tissues, nanomaterials can spare healthy cells from the harsh side effects often associated with conventional chemotherapy. This focused approach not only improves patient quality of life but also maximizes the destructive impact on tumors, leading to more favorable treatment outcomes. The principles behind the design of these advanced delivery systems are continuously evolving, opening new avenues for overcoming drug resistance and improving long-term remission rates. Poorly water-soluble drugs often suffer from low bioavailability, a challenge actively addressed by nanotechnology [3].

This inherent issue limits the therapeutic potential of many promising drug candidates. Nanotechnology offers a suite of innovative strategies, including the development of nanocrystals and various lipid-based nanocarriers, specifically engineered to boost drug solubility and, consequently, their absorption within the body. These methods provide promising avenues for reformulating existing drugs and developing new ones that would otherwise be impractical due to their dissolution properties. The integration of smart nanomaterials into cancer therapy offers innovative solutions for targeted drug delivery, minimizing side effects and improving treatment outcomes [4].

These responsive nanomaterials are designed to react to specific physiological triggers, such as pH changes, temperature fluctuations, or enzyme activity, which are often characteristic of the tumor microenvironment. This intelligent targeting ensures that drugs are released precisely where and when needed, optimizing therapeutic impact while drastically reducing off-target effects. This revolutionary approach has the potential to redefine precision oncology by making treatments safer and significantly more effective for patients. Improving the bioavailability of active pharmaceutical ingredients remains a core challenge in medicinal chemistry [5].

Nanotechnology provides diverse solutions to this persistent problem. From advanced solid lipid nanoparticles to intricate polymeric micelles, these innovative strategies are designed to enhance both drug absorption and stability. By protecting drugs from premature degradation and facilitating their passage across biological barriers, nanotechnology allows for more efficient drug action. Nanoparticle-based drug delivery systems offer significant advantages for treating infectious diseases by improving drug targeting, reducing toxicity, and enhancing therapeutic efficacy [6].

These systems are becoming indispensable in the fight against bacterial, viral, and parasitic infections. By encapsulating antimicrobial agents within nanoparticles, it becomes possible to deliver higher drug concentrations to infection sites while minimizing systemic exposure and associated side effects. This targeted delivery mechanism is critical for overcoming drug resistance and developing novel antimicrobial therapies that are both potent and safe, promising a transformative future for infectious disease management. Lipid nanoparticles have emerged as a versatile platform in drug delivery, offering excellent biocompatibility and high encapsulation efficiency [7].

These particles are particularly notable for their ability to carry a wide range of therapeutic molecules, from small drugs to complex nucleic acids, with remarkable stability. Their inherent biocompatibility makes them well-tolerated by the body, reducing concerns about adverse reactions. Advanced nanoparticle delivery systems are revolutionizing cancer therapy by enabling precise drug targeting, minimizing systemic side effects, and enhancing therapeutic outcomes [8].

---

\*Correspondence to: Emily L. Hayes, Department of Medicinal Chemistry, University of Oxford, United Kingdom. E-mail: emily.hayes@email.com

Received: 02-May-2025, Manuscript No. AAPCCS-25-176; Editor assigned: 06-May-2025, Pre QC No. AAPCCS-25-176 (PQ); Reviewed: 26-May-2025, QC No. AAPCCS-25-176; Revised: 04-Jun-2025, Manuscript No. AAPCCS-25-176 (R); Published: 13-Jun-2025, DOI: 10.35841/aapccs-9.2.176

The continuous innovation in nanoparticle design and their intricate mechanisms of action are providing crucial insights into developing oncological treatments that are not only more effective but also considerably safer for patients. By focusing on targeted approaches, these systems can deliver potent therapies directly to cancer cells, reducing the overall burden on the patient's body and paving the way for personalized cancer medicine with improved prognosis. Polymeric nanoparticles represent a promising avenue for oral drug delivery, addressing issues of poor solubility, degradation, and low bioavailability [9].

The oral route is often preferred for drug administration due to its convenience, but it presents numerous challenges. Polymeric nanoparticles are specifically engineered to overcome these hurdles, enhancing the absorption and therapeutic efficacy of orally administered drugs. Nanomedicine represents a frontier in advanced therapeutics, offering unparalleled precision in drug delivery and enhanced bioavailability [10].

This burgeoning field is critically examining its current state, discussing its future prospects, and confronting existing challenges. The potential of nanomedicine to revolutionize patient care through innovative drug design and sophisticated delivery strategies is immense, promising a future where treatments are more tailored, more effective, and have fewer side effects.

## Conclusion

Nanotechnology is fundamentally changing drug delivery by addressing significant challenges in medicine, such as poor drug solubility, enzymatic degradation, and first-pass metabolism, which hinder drug bioavailability. Nanocarriers are specifically designed to overcome these barriers, leading to improved oral absorption and enhanced therapeutic efficacy for various drugs. This field offers diverse strategies, from solid lipid nanoparticles to polymeric micelles, demonstrating practical implications for more effective drug formulations. The use of nanomaterials extends to targeted cancer therapy, where they enable precise drug delivery, reduce systemic toxicity, and improve treatment outcomes by leveraging smart and responsive designs. Beyond cancer, nanoparticle-based systems show considerable promise for combating infectious diseases, including bacterial, viral, and parasitic infections, by improving drug targeting and reducing side effects. Furthermore, poorly water-

soluble drugs, a major pharmaceutical challenge, benefit greatly from nanotechnology-based approaches like nanocrystals and lipid-based nanocarriers, which boost solubility and absorption. Lipid nanoparticles, known for their biocompatibility and high encapsulation efficiency, are proving versatile platforms, enhancing drug bioavailability and facilitating targeted delivery across many therapeutic applications. Polymeric nanoparticles are also advancing oral drug delivery by tackling solubility, degradation, and bioavailability issues, offering new opportunities for improved absorption. Overall, nanomedicine stands as a frontier in advanced therapeutics, promising unparalleled precision and enhanced bioavailability. It examines current landscapes, future prospects, and challenges, highlighting its potential to transform patient care through innovative drug design and delivery.

## References

1. Priyanka C, Sarwar B, Mohd N. Nanocarriers for improved oral bioavailability of drugs: *A comprehensive review. Drug Discov Today.* 2020;25:1475-1488.
2. Mohamed A. M. A, Mohamed A. E, Hany M. A. E. Recent advances in drug delivery systems for targeted cancer therapy: *Nanomaterials and their biomedical applications. J Control Release.* 2022;349:110-128.
3. Vinit K, Rajesh K, Sanjay S. Nanotechnology-based approaches for enhancing the bioavailability of poorly water-soluble drugs: *Current status and future perspectives. J Control Release.* 2021;339:44-62.
4. Xiaohui W, Mengmeng Z, Meng L. *Smart Nanomaterials in Drug Delivery for Cancer Therapy. J Med Chem.* 2020;63:8645-8664.
5. M. S. S, P. K. M, S. K. N. Recent advances in nanotechnology-based strategies for improving the bioavailability of active pharmaceutical ingredients. *J Drug Deliv Sci Technol.* 2023;82:104277.
6. B. A, P. V. R, T. V. K. Nanoparticle-based drug delivery systems for infectious diseases: *A review. Int J Pharm.* 2023;641:123048.
7. Mengchen L, Yi F, Xiaowei G. Lipid nanoparticles for drug delivery: from fundamentals to clinical applications. *J Nanobiotechnology.* 2023;21:319.
8. Xiacong Z, Xiaohong S, Zhixuan C. *Advanced Nanoparticle Delivery Systems in the Field of Cancer Therapy. Front Pharmacol.* 2021;12:686701.
9. Pooja S, Saurabh K, Meenu S. Polymeric Nanoparticles for Oral Drug Delivery: *Challenges and Opportunities. J Pharm Sci.* 2022;111:2284-2300.
10. Xiaoli L, Guanglei H, Chenyang L. Nanomedicine for advanced therapies: *Future perspectives and challenges. Adv Drug Deliv Rev.* 2023;194:114757.

**Citation:** Hayes EL. *Nanomedicine: Precision drug delivery and bioavailability. J Pharm Chem Chem Sci.* 2025;09(02):176.